Cellectis, Precision BioSciences genomics news

Precision filed suit in the U.S. District Court for the Eastern District of North Carolina alleging that Cellectis is infringing on U.S. Patent No. 8,021,867 through the sale of meganucleases targeting the human RAG1 gene, HIV-1 genome and the GS gene in Chinese hamster ovary (CHO) cells. Patent '867 covers engineered meganucleases with altered DNA-cleavage specificity and modified DNA-binding affinity and/or modified dimerization properties. Precision has exclusive rights to the patent from Duke University. Precision is seeking a permanent injunction to prevent Cellectis from infringing on the patent as well as awards in damages and court fees. The U.S. Patent and Trademark Office issued the '867 patent last month. ...